Eli Lilly (LLY) Other financing activities (2009 - 2026)

Eli Lilly (LLY) has reported Other financing activities for 16 consecutive years, with -$591.0 million the latest figure, recorded in Q1 2026.

• Other financing activities for Q1 2026 came in at -$591.0 million, up 13.85% year-over-year; the trailing twelve-month figure through Mar 2026 was -$677.0 million (up 14.0% YoY), and the FY2025 annual result was -$772.0 million, down 57.23% from the prior year.
• Other financing activities was -$591.0 million for Q1 2026 at Eli Lilly, down from -$25.1 million in the prior quarter.
• Over five years, Other financing activities peaked at -$5.2 million in Q3 2022 and troughed at -$686.0 million in Q1 2025.
• Average Other financing activities over 5 years is -$146.9 million, with a median of -$30.7 million recorded in 2025.
• The widest YoY moves for Other financing activities: up 48.99% in 2022, down 2183.33% in 2022.
• Over 5 years, Other financing activities stood at -$13.7 million in 2022, then plunged by 130.66% to -$31.6 million in 2023, then plunged by 45.25% to -$45.9 million in 2024, then soared by 45.32% to -$25.1 million in 2025, then slumped by 2254.58% to -$591.0 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were -$591.0 million in Q1 2026, -$25.1 million in Q4 2025, and -$30.2 million in Q3 2025.